A Safety and Efficacy Trial of Recombinant Human Activated Protein C in Both Early-Onset Pre-Eclampsia and Severe Postpartum Pre-Eclampsia.

Trial Profile

A Safety and Efficacy Trial of Recombinant Human Activated Protein C in Both Early-Onset Pre-Eclampsia and Severe Postpartum Pre-Eclampsia.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2011

At a glance

  • Drugs Drotrecogin alfa (Primary)
  • Indications Preeclampsia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Aug 2008 Planned end date changed from 1 Dec 2006 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 06 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top